National Cancer Institute (NCI)s

National Cancer Institute (NCI)

426 Protocols (243 Active Accrual of new subjects, 183 Follow-up of previously enrolled subjects)

Active Accrual, Protocols Recruiting New Patients 
* 19-C-0017:
Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

* 19-C-0002:
A Phase II Study of M7824 in Subjects with Recurrent Respiratory Papillomatosis

* 18-C-0147:
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid Tumors

* 18-C-0143:
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy

* 18-C-0138:
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

* 18-C-0136:
Phase II Study of the Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

* 18-C-0135:
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

* 18-C-0130:
PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

* 18-C-0126:
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)

* 18-C-0125:
A Phase I Clinical Trial of T cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple Myeloma

* 18-C-0122:
Phase IB Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas

* 18-C-0119:
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 with Inoperable, Progressive/Symptomatic Plexiform Neurofibromas

* 18-C-0110:
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

* 18-C-0097:
Phase II Study of Olaparib in Subjects with Malignant Mesothelioma

* 18-C-0096:
A Single Arm Phase II Study Combining CRLX101, a Nanoparticle Camptothecin, with Enzalutamide in Patients with Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

* 18-C-0093:
Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials

* 18-C-0088:
Use of CV301 for the Treatment of Triple Positive Metastatic Breast Cancer

* 18-C-0080:
Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children with High Grade Brain Tumors and Their Caregivers

* 18-C-0078:
Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, ALT-803 and Epacadostat (QuEST1)

* 18-C-0076:
Bicalutamide With or Without Metformin for Biochemical Recurrence in Prostate Cancer Patients (BIMET-1)

* 18-C-0074:
A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a messenger RNA (mRNA)-based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

* 18-C-0073:
Treatment of Patients with Castration Resistant Prostate Cancer using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccine

* 18-C-0070:
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

* 18-C-0061:
A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination with Gemcitabine in Adults with Previously Treated Advanced Adenocarcinoma of the Pancreas

* 18-C-0059:
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

* 18-C-0058:
The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

* 18-C-0056:
M7824 in Subjects with HPV Associated Malignancies

* 18-C-0049:
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive against Mutated Neoantigens in People with Metastatic Cancer

* 18-C-0043:
Generation of Cancer Antigen-Specific T-cells from Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential Future Therapy

* 18-C-0038:
Long Term Follow-up of Subjects Exposed to NY-ESO-1c259T, a Genetically Engineered NY-ESO-1 Specific T Cell Receptor

* 18-C-0034:
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

* 18-C-0033:
Phase I Study of Recombinant Interleukin-15 in Combination with Checkpoint Inhibitors Nivolumab and Ipilimumab in People with Refractory Cancers

* 18-C-0028:
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

* 18-C-0017:
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

* 18-C-0014:
Phase I Trial of 5-aza-4'-thio-2'-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors

* 18-C-0008:
Phase III randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation

* 18-C-0005:
Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

* 17-C-0177:
A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

* 17-C-0175:
CC-4047-BRN-001: A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults with Recurrent or Progressive Primary Brain Tumors

* 17-C-0174:
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

* 17-C-0172:
Phase IIB Study of Cediranib and Olaparib Combination in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Fallopian Tubal and/or Primary Peritoneal Cancer without Germline BRCA Mutation, Who Had Prior Bevacizumab (D8488C0001)

* 17-C-0164:
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

* 17-C-0157:
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with BCG

* 17-C-0156:
Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute

* 17-C-0153:
Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior Radiotherapy

* 17-C-0149:
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma(PCNSL), and other Extranodal Diffuse Large B-cell Lymphomas

* 17-C-0144:
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations

* 17-C-0140:
Phase I/II Evaluation of the Immune Checkpoint Inhibitor, Pembrolizumab in Combination with Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, or Unresectable Locally Advanced or Metastatic Non-small Cell Lung Cancer

* 17-C-0137:
Leukapheresis for CAR-Therapy Manufacturing

* 17-C-0127:
Phase 1b Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

* 17-C-0125:
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

* 17-C-0117:
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Advanced Solid Malignancies

* 17-C-0116:
A Phase I Study of Immunotherapy with E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

* 17-C-0115:
Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

* 17-C-0113:
Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A 1101 Patients

* 17-C-0109:
(18)F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

* 17-C-0105:
Prospective Study of Clonal Evolution in Follicular Lymphoma

* 17-C-0102:
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Select Rare CNS Cancers

* 17-C-0100:
Collection of Malignant Ascites, Pleural Fluid, and Blood from Patients with Solid Tumors

* 17-C-0092:
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer

* 17-C-0090:
DART: Dual Anti-CTLA-4 And Anti-Pd-1 Blockade In Rare Tumors

* 17-C-0089:
Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate Cancer

* 17-C-0088:
A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer

* 17-C-0087:
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

* 17-C-0084:
A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

* 17-C-0082:
A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination with Capecitabine and Oxaliplatin (CAPOX) in Subjects with Advanced Biliary Tract Carcinoma (BTC)

* 17-C-0074:
A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma

* 17-C-0070:
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer with Positive Peritoneal Cytology

* 17-C-0066:
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy

* 17-C-0061:
Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

* 17-C-0057:
A Randomized Phase II Trial of Standard of Care Alone or in Combination with Ad-CEA Vaccine and Avelumab in Patients with Previously Untreated Metastatic or Unresectable Colorectal Cancer

* 17-C-0052:
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor, alone or in combination with Oral Decitabine/Tetrahydrouridine asSecond Line Therapy for Non-Small Cell Lung Cancer

* 17-C-0049:
A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination with the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients with Embryonal and Alveolar Rhabdomyosarcoma

* 17-C-0048:
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

* 17-C-0044:
Prospective Evaluation and Molecular Profiling in Patients with Gastric Tumors

* 17-C-0043:
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

* 17-C-0038:
A Phase Ib Open Label, Dose Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid Tumors

* 17-C-0034:
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

* 17-C-0028:
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo ) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia

* 17-C-0027:
Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation

* 17-C-0023:
A Phase 1/2 Trial of CV301 In Combination with Anti-PD-1 Therapy Versus Anti-PD-1 Therapy Alone in Subjects with Non-Small Cell Lung Cancer

* 17-C-0012:
Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors

* 17-C-0011:
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

* 17-C-0009:
Phase I Trial of TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and Glioblastoma

* 17-C-0007:
Phase I/II Study of PROSTVAC in Combination with Nivolumab in Men with Prostate Cancer

* 16-C-0171:
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R(2)) In Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma

* 16-C-0154:
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 with or without PD-1 Blockade for HPV-Associated Cancers

* 16-C-0151:
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System

* 16-C-0138:
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy

* 16-C-0135:
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

* 16-C-0131:
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70 Expressing Cancers

* 16-C-0128:
A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

* 16-C-0121:
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

* 16-C-0109:
Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519 in Patients with Advanced Solid Tumors

* 16-C-0107:
A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung Cancer

* 16-C-0097:
Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma

* 16-C-0094:
A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (SCT)

* 16-C-0092:
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)

* 16-C-0091:
Long-Term Follow-up of Subjects Treated with bb2121

* 16-C-0087:
Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in Patients with Refractory Solid Tumors

Next 100 Protocols